posted on 2023-03-31, 18:23authored byChristopher M. Jackson, Christina M. Kochel, Christopher J. Nirschl, Nicholas M. Durham, Jacob Ruzevick, Angela Alme, Brian J. Francica, Jimmy Elias, Andrew Daniels, Thomas W. Dubensky, Peter Lauer, Dirk G. Brockstedt, Emily G. Baxi, Peter A. Calabresi, Janis M. Taube, Carlos A. Pardo, Henry Brem, Drew M. Pardoll, Michael Lim, Charles G. Drake
Brain tumors are more tolerogenic than flank or lung tumors. (A) Representative FACS plots from tumor draining lymph nodes of mice with B16-OVA brain, flank, or lung tumors. (B) Summary graphs of the percentage of daughter cells producing IFN-γ recovered from the tumor draining lymph nodes of mice with B16-OVA brain, flank, or lung tumors (5 mice/group).
Funding
NIH
the Patrick C. Walsh Fund, the OneInSix Foundation, the Prostate Cancer Foundation, and the Melanoma Research Association
Howard Hughes Medical Fellows Research Program
The Bart McLean Fund for Neuroimmunology Research-Project Restore